-
11:13:08 PM

SRPT Stock News

05/12/23 7:02 PM
Nasdaq : SRPT
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration Cellular, Tissue and Gene Therapies Advisory Committee voted 8 to 6 in support of accelerated approval of SRP-9001 for the treatment of ambulatory patients with Duchenne muscular dystrophy with a confirmed...
RHEA-AI
neutral
05/02/23 4:05 PM
Nasdaq : SRPT
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
With EXONDYS 51, VYONDYS 53, and AMONDYS 45, we once again exceeded analyst estimates, with total revenue for the quarter reaching $253.5 million and net product revenue standing at $231.5 million and growing at 23% versus the same quarter of prior year. FDA advisory committee meeting for SRP-9001 to be held on May 12, 2023: In March, the Company announced that...
RHEA-AI
neutral
04/10/23 9:37 AM
Nasdaq : SRPT
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced that the date of the U.S. Food and Drug Administration’ s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 biologics license application is May 12, 2023. “We look forward to sharing the wealth of evidence supporting the...
RHEA-AI
neutral